Advertisement
Loading...

CytoTools AG

T5O.DEXETRA
Healthcare
Biotechnology
0.32
0.00(0.00%)
German Market opens in 15h 28m

CytoTools AG (T5O.DE) Stock Competitors & Peer Comparison

See (T5O.DE) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
T5O.DE€0.32+0.00%164.4K-0.25-€1.29N/A
NOV.DE€39.22+0.27%173.6B10.65€3.67+4.02%
VX1.DE€363.80+0.37%92.5B25.26€14.40N/A
DUL.DE€251.95+0.00%33.6B127.89€1.97N/A
22UA.F€79.30-1.00%20.1B-15.64-€5.07N/A
0QF.F€46.51+12.56%18.5B-6.69-€6.95N/A
BM8.DE€61.96-1.71%11.8B88.51€0.70N/A
EX9.DE€32.28+1.22%9.2B35.47€0.91N/A
BBZA.DE€48.65-0.41%2.7B-5.66-€8.60+5.07%
MOR.DE€67.25-0.66%2.5B-12.16-€5.53N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

T5O.DE vs NOV.DE Comparison May 2026

T5O.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, T5O.DE stands at 164.4K. In comparison, NOV.DE has a market cap of 173.6B. Regarding current trading prices, T5O.DE is priced at €0.32, while NOV.DE trades at €39.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

T5O.DE currently has a P/E ratio of -0.25, whereas NOV.DE's P/E ratio is 10.65. In terms of profitability, T5O.DE's ROE is -1.91%, compared to NOV.DE's ROE of +0.66%. Regarding short-term risk, T5O.DE is more volatile compared to NOV.DE. This indicates potentially higher risk in terms of short-term price fluctuations for T5O.DE.Check NOV.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions